Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 18% – Here’s Why

Corcept Therapeutics Incorporated (NASDAQ:CORT) traded down 18% during mid-day trading on Thursday . The company traded as low as $36.86 and last traded at $32.6360. 511,437 shares were traded during trading, a decline of 75% from the average session volume of 2,045,150 shares. The stock had previously closed at $39.82.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: Multiple temporary trading halts (LULD pauses) occurred this morning as volatility spiked; these are market‑mechanism pauses, not company announcements.
• Neutral Sentiment: Corcept plans to report Q4 and full‑year 2025 results and hold a corporate update and conference call on Feb. 24 — this event could provide management’s view on Korlym revenue risk, relacorilant strategy and legal contingencies. Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
• Neutral Sentiment: Short‑interest data in the feed appear anomalous (reported as zero); ignore for position sizing until broker/clearing data are confirmed.
• Negative Sentiment: An appeals court affirmed that Teva’s proposed generic does not infringe two Korlym‑related patents, effectively clearing Teva to pursue a generic launch — this is the primary immediate catalyst for the selloff because it threatens Korlym revenue. Corcept Therapeutics Stock Plunges As Court Clears Teva Generic
• Negative Sentiment: Market coverage and headlines are amplifying the move; analysts/news sites report the stock “crashing” after the patent defeat, which can accelerate selling and volatility. Corcept Therapeutics Stock Crashes 21% after Patent Defeat to Teva
• Negative Sentiment: Corcept is already dealing with an FDA Complete Response Letter for relacorilant; valuation and investor reactions to that CRL remain relevant and magnify downside risk as a late product‑pipeline setback. A Look At Corcept Therapeutics (CORT) Valuation After FDA Complete Response Letter For Relacorilant
• Negative Sentiment: Separately, Kaplan Fox has alerted investors about a securities‑law probe into Corcept; ongoing investigations increase legal and disclosure risk and can sustain selling pressure until resolved. CORCEPT THERAPEUTICS ALERT: Corcept Therapeutics, Inc. (CORT) are Encouraged to Contact Kaplan Fox

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Zacks Research downgraded Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Truist Financial set a $50.00 price objective on Corcept Therapeutics in a research note on Wednesday, December 31st. UBS Group initiated coverage on shares of Corcept Therapeutics in a research report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price for the company. HC Wainwright upped their target price on shares of Corcept Therapeutics from $90.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $83.50.

Corcept Therapeutics Price Performance

The firm has a market capitalization of $3.53 billion, a P/E ratio of 38.36 and a beta of 0.25. The stock’s fifty day simple moving average is $51.26 and its 200 day simple moving average is $67.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07.

Insiders Place Their Bets

In other news, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.52, for a total transaction of $1,590,400.00. Following the sale, the insider owned 7,904 shares in the company, valued at approximately $628,526.08. The trade was a 71.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph Douglas Lyon sold 5,000 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $79.53, for a total transaction of $397,650.00. Following the completion of the transaction, the insider directly owned 10,277 shares of the company’s stock, valued at $817,329.81. The trade was a 32.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 129,500 shares of company stock valued at $8,665,500. Company insiders own 20.80% of the company’s stock.

Institutional Trading of Corcept Therapeutics

Several large investors have recently bought and sold shares of the stock. Abacus FCF Advisors LLC acquired a new stake in Corcept Therapeutics during the 3rd quarter worth $3,238,000. Pacer Advisors Inc. grew its stake in Corcept Therapeutics by 6,796.7% during the 3rd quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company’s stock valued at $32,459,000 after acquiring an additional 384,896 shares in the last quarter. Brown Capital Management LLC acquired a new stake in Corcept Therapeutics in the 3rd quarter valued at about $19,950,000. Cerity Partners LLC lifted its stake in Corcept Therapeutics by 21.4% in the 2nd quarter. Cerity Partners LLC now owns 746,593 shares of the biotechnology company’s stock worth $54,800,000 after purchasing an additional 131,799 shares in the last quarter. Finally, Synergy Asset Management LLC boosted its holdings in shares of Corcept Therapeutics by 96.1% during the 3rd quarter. Synergy Asset Management LLC now owns 506,856 shares of the biotechnology company’s stock worth $39,615,000 after purchasing an additional 248,362 shares during the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.